Premium
Enhanced elimination of warfarin during treatment with cholestyramine.
Author(s) -
Jahnchen E,
Meinertz T,
Gilfrich HJ,
Kersting F,
Groth U
Publication year - 1978
Publication title -
british journal of clinical pharmacology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.216
H-Index - 146
eISSN - 1365-2125
pISSN - 0306-5251
DOI - 10.1111/j.1365-2125.1978.tb01651.x
Subject(s) - cholestyramine , warfarin , concomitant , anticoagulant , enterohepatic circulation , medicine , half life , prothrombin time , pharmacokinetics , pharmacology , chemistry , bile acid , cholesterol , atrial fibrillation
1 The elimination and anticoagulant activity of a single intravenous dose of warfarin (1.0‐1.2 mg/kg) without and with concomitant cholestyramine treatment (about 4 g three times daily) was studied in five healthy male subjects. 2 Cholestyramine treatment decreased the biological half‐life of plasma warfarin (from a mean value of 2 days − 1.3 days) and increased the total clearance of this drug (from a mean value of 37 ml kg‐1 day‐1–53 ml kg‐1 day‐1). 3 The total anticoagulant effect per dose of warfarin, as measured by the area under the effect v time curve, was also reduced by cholestyramine (average reduction of about 25%). 4 Warfarin possibly undergoes enterohepatic recycling in man which can be interrupted by cholestyramine.